Cutaneous Lupus Erythematosus Market Growth Analysis By DelveInsight
Cutaneous Lupus Erythematosus (CLE) is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus where the symptoms are restricted to the skin. The pathophysiology of cutaneous lupus erythematosus (CLE) encompasses the complex interactions between genetics, the environment, and cells and their products, central to the pathogenesis is loss of immune tolerance and upregulation of the interferon-α (IFN-α) signaling.
DelveInsight's "Cutaneous Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Cutaneous Lupus Erythematosus market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Cutaneous Lupus Erythematosus market shares of the individual therapies, a detailed current Cutaneous Lupus Erythematosus treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Cutaneous Lupus Erythematosus Market Key Facts
- The total prevalent population of Cutaneous Lupus Erythematosus in 7MM was found to be 327,569 in 2017. Among all the countries, the United States has a higher population of CLE with 182,765 cases in 2017.
- Among the EU5 countries, UK has the highest prevalent population with 49,292 cases, followed by Germany while Spain on the other hand had the lowest cases, whereas Japan had 22,398 cases of CLE in 2017.
- The lowest prevalent population of Cutaneous Lupus Erythematosus (CLE) was recorded in Japan.
- As per DelveInsight’s analysis, women are found to be affected more with Cutaneous Lupus Erythematosus than men. In 2017, there were 71,279 prevalent cases of CLE in men and 111,487 prevalent cases of CLE among women in the US.
Cutaneous Lupus Erythematosus Market Growth
The Cutaneous Lupus Erythematosus market analysis section of the report helps to understand the current and forecasted Cutaneous Lupus Erythematosus market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers.
The report gives complete detail of Cutaneous Lupus Erythematosus market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Cutaneous Lupus Erythematosus Therapeutics Market
There are no FDA-approved therapies for Cutaneous Lupus Erythematosus, and CLE can be managed but so far not cured. The current Cutaneous Lupus Erythematosus market is majorly driven by the evidence-based approach with the use of Topical therapies. The market is filled with antimalarials as first-line and long-term agents with the use of Hydroxychloroquine, Quinacrine, and Chloroquine. Currently, several companies with their continuous efforts in research and development are developing Cutaneous Lupus Erythematosus therapies, which are expected to enter the market by 2030. These advances give hope that safe and effective disease-modifying therapies for Cutaneous Lupus Erythematosus might finally be within reach.
To fulfill the current unmet need, the Cutaneous Lupus Erythematosus market is expanding at rapid speed across the globe due to the surging prevalence of lupus as well as the ongoing medical advancements in treating systemic lupus erythematosus. The increased research and development activities for lupus can be considered a propelling factor for Cutaneous Lupus Erythematosus (CLE) Market growth. Cutaneous Lupus Erythematosus Companies involved in developing therapies include Pfizer, Biogen, Galapagos NV /Gilead Sciences, Viela Bio, LEO Pharma, Gilead Sciences, Novartis, and many others. Cutaneous Lupus Erythematosus Therapies Covered in the report include Etanercept, BIIB059, Filgotinib, VIB7734, Delgocitinib, GS-9876, Secukinumab, Tofacitinib, and many others.
Cutaneous Lupus Erythematosus Epidemiology Forecast
Cutaneous Lupus Erythematosus Epidemiology Segmentation
- Total Prevalent Pool of Cutaneous Lupus Erythematosus
- Diagnosed Prevalent Pool of Cutaneous Lupus Erythematosus
- Gender-specific Prevalent Pool of Cutaneous Lupus Erythematosus
- Type-specific Prevalent Pool of Cutaneous Lupus Erythematosus
- Severity-specific Prevalent Pool of Cutaneous Lupus Erythematosus (CLE)
The Cutaneous Lupus Erythematosus epidemiology section covers insights about historical and current Cutaneous Lupus Erythematosus patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Cutaneous Lupus Erythematosus Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Cutaneous Lupus Erythematosus Market Growth